Prelude Therapeutics Incorporated (PRLD) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Wilmington, DE, United States. The current CEO is Krishna Vaddi.
PRLD has IPO date of 2020-09-25, 131 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $245.2M.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
